In Vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay

1986 ◽  
Vol 22 (8) ◽  
pp. 921-926 ◽  
Author(s):  
Werner Scheithauer ◽  
Daniel D. von Hoff ◽  
Gary M. Clark ◽  
Joan L. Shillis ◽  
Edward F. Elslager
Keyword(s):  
Human Tumor ◽  
Vitro Activity ◽  
Antitumor Antibiotic ◽  
The Novel ◽  
In Vitro Activity ◽  
Cloning Assay ◽  
Human Tumor Cloning

In vitro activity of menogaril and N-demethylmenogaril in a human tumor cloning assay

1986 ◽  
Vol 22 (3) ◽  
pp. 245-249 ◽  
Author(s):  
P. Dodion ◽  
C. Sanders ◽  
W. Rombaut ◽  
M. Rozencweig ◽  
M.M. Kitt ◽  
...  
Keyword(s):  
Human Tumor ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Cloning Assay ◽  
Human Tumor Cloning

Ultrastructural Correlations between Clonal Human Tumor Colonies and in Vivo Neoplasms

1982 ◽  
Vol 40 ◽  
pp. 210-211
Author(s):  
M.J. Murphy ◽  
R.R. Price ◽  
J.C. Sloman
Keyword(s):  
Cultured Cells ◽  
Human Tumor ◽  
Cell Type ◽  
Tumor Mass ◽  
Initial Cell ◽  
Cloning Assay ◽  
Human Tumor Cloning ◽  
The Relationship

The in vitro human tumor cloning assay originally described by Salmon and Hamburger has been applied recently to the investigation of differential anti-tumor drug sensitivities over a broad range of human neoplasms. A major problem in the acceptance of this technique has been the question of the relationship between the cultured cells and the original patient tumor, i.e., whether the colonies that develop derive from the neoplasm or from some other cell type within the initial cell population. A study of the ultrastructural morphology of the cultured cells vs. patient tumor has therefore been undertaken to resolve this question. Direct correlation was assured by division of a common tumor mass at surgical resection, one biopsy being fixed for TEM studies, the second being rapidly transported to the laboratory for culture.

scholarly journals In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis

2017 ◽  
Vol 72 (5) ◽  
pp. 1355-1358 ◽  
Author(s):  
Dina A. Boikov ◽  
Jeffrey B. Locke ◽  
Kenneth D. James ◽  
Ken Bartizal ◽  
Jack D. Sobel
Keyword(s):  
Vulvovaginal Candidiasis ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Candida Spp

In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile

2020 ◽  
Author(s):  
Beverly Murray ◽  
Cindy Wolfe ◽  
Andrea Marra ◽  
Chris Pillar ◽  
Dean Shinabarger
Keyword(s):  
Therapeutic Potential ◽  
Oral Treatment ◽  
Clinical Development ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Time Kill

Abstract Background Ibezapolstat (ACX-362E) is the first DNA polymerase IIIC inhibitor undergoing clinical development for the oral treatment of Clostridioides difficile infection (CDI). Methods In this study, the in vitro activity of ibezapolstat was evaluated against a panel of 104 isolates of C. difficile, including those with characterized ribotypes (e.g. 027 and 078) and those producing toxin A or B and was shown to have similar activity to those of comparators against these strains. Results The overall MIC50/90 (mg/L) for ibezapolstat against evaluated C. difficile was 2/4, compared with 0.5/4 for metronidazole, 1/4 for vancomycin and 0.5/2 for fidaxomicin. In addition, the bactericidal activity of ibezapolstat was evaluated against actively growing C. difficile by determining the MBC against three C. difficile isolates. Time–kill kinetic assays were additionally performed against the three C. difficile isolates, with metronidazole and vancomycin as comparators. Conclusions The killing of C. difficile by ibezapolstat was observed to occur at concentrations similar to its MIC, as demonstrated by MBC:MIC ratios and reflected in time–kill kinetic assays. This activity highlights the therapeutic potential of ibezapolstat for the treatment of CDI.

scholarly journals Novel Administration of Clofazimine for the Treatment of Mycobacterium avium Infection

2020 ◽  
Vol 7 (6) ◽  
Author(s):  
Ethan Valinetz ◽  
Helen Stankiewicz Karita ◽  
Paul S Pottinger ◽  
Rupali Jain
Keyword(s):  
Cystic Fibrosis ◽  
Lung Transplantation ◽  
Mycobacterium Avium ◽  
Nontuberculous Mycobacteria ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Avium Infection ◽  
Mycobacterium Avium Infection

Abstract Clofazimine has demonstrated in vitro activity against many nontuberculous mycobacteria. We present the case of a woman with cystic fibrosis who developed disseminated macrolide-resistant Mycobacterium avium infection following lung transplantation treated in part with clofazimine. We describe the novel administration of clofazimine via gastrostomy tube.

scholarly journals In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi

2018 ◽  
Author(s):  
Chayanika Biswas ◽  
Derek Law ◽  
Michael Birch ◽  
Catriona Halliday ◽  
Tania C Sorrell ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Antifungal Compound ◽  
The Novel ◽  
In Vitro Activity

In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia

2002 ◽  
Vol 13 (7) ◽  
pp. 735-742 ◽  
Author(s):  
B-M Frost ◽  
G Lönnerholm ◽  
P Nygren ◽  
R Larsson ◽  
E Lindhagen
Keyword(s):  
Acute Leukemia ◽  
Vitro Activity ◽  
Cytotoxic Agent ◽  
The Novel ◽  
In Vitro Activity ◽  
Chs 828 ◽  
Childhood Acute Leukemia
Sign in / Sign up

Export Citation Format

Share Document